NCT05978557Recruiting
Brain Slice Explants to Predict Drug Response in Brain Tumors
A Feasibility Study to Determine if a Novel Patient-derived Explant Platform Can Produce Drug Sensitivity Scores Within a Clinically Relevant Time Frame in Patients With CNS Tumors
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
This biospecimen collection study will evaluate the feasibility of engrafting and testing resected Central nervous system (CNS) tumors tumor tissue ex vivo to estimate drug response, in pediatric and adult subjects. CNS tumors display remarkable heterogeneity and unfortunately there are no reliable precision oncology platforms that can identify the most effective therapy for each patient. Recent work has demonstrated the success of functional precision oncology platforms using patient-derived explant (PDE) at predicting drug response in various cancers. Since PDEs maintain important aspects of tumor heterogeneity they may prove effective as functional models for CNS tumors. The purpose of this study is to explore the feasibility of using a novel PDE platform to generate drug sensitivity scores from patients with central nervous system tumors in Pediatric and adult subjects having low- or high-grade CNS tumors resected. The secondary objective is to estimate the proportion of successfully scaled PDEs generated per given tumor size.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 28 Jul 2023
- Start date
- 27 Jul 2023
- Primary completion date
- 1 Mar 2028
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Diseases
- Childhood cancers
- NCT number
- NCT05978557
What you commit to
- Study type: Observational
- Planned participants: 50
- From 27 Jul 2023 to the primary completion date, 1 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- All subjects must not meet any of the following exclusion criteria prior to enrollment to participate in this study:
- Any serious medical or psychiatric disorder that would interfere with the subject's ability to give informed consent.
Other
- Incarcerated individuals.
Who the study is looking for
- Written informed consent obtained to participate in the study and HIPAA authorization for the release of personal health information or written assent and parental consent for pediatric subjects or surrogate consent provided by the subject's legally authorized guardians.
- A diagnosis of a tumor residing in the central nervous system with surgery plan to have surgical resection.
- The subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designer.
Criteria the registry did not label
- In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UNC Lineberger Comprehensive Cancer Center Coordinator of this site? Confirm its status | Chapel Hill | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.